Mutational signature analysis of these five pediatric tumors revealed that only the tumor with pathogenic homozygous BRCA2 mutation, that is, biallelic inactivation, showed SBS3 and ID6 signature activity (Fig. 4c and Supplementary Table 14). This evidence concerns the gene BRCA2 and neoplasm.